Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3789-3793

  Vaudaux, Pierre ^a   Gjinovci, Asllan ^a   Bento, Manuela ^a   Li, Dongmei ^a   Schrenzel, Jacques ^a   Lew, Daniel P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTOBIPROLE MEDOCARIL; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; FOREIGN BODY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TREATMENT OUTCOME;

ANIMALS; CEPHALOSPORINS; FOREIGN BODIES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUTATION; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 24144435354     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3789-3793.2005     Document Type: Article

References (49)

1. Abbanat, D., M. Macielag, and K. Bush. 2003. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs 12:379-399.
2. Anderegg, T. R., R. N. Jones, and H. S. Sader. 2004. Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. J. Clin. Microbiol. 42:3356-3358.
3. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
4. Bernard, L., P. Hoffmeyer, M. Assal, P. Vaudaux, J. Schrenzel, and D. Lew. 2004. Trends in the treatment of orthopaedic prosthetic infections. J. Antimicrob. Chemother. 53:127-129.
5. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
6. Bradley, J. S. 2005. Newer antistaphylococcal agents. Curr. Opin. Pediatr. 17:71-77.
7. Cagni, A., C. Chuard, P. Vaudaux, J. Schrenzel, and D. P. Lew. 1995. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1655-1660.
8. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
9. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin- intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
10. Chandrasekar, P. H., D. P. Levine, S. Price, and M. J. Rybak. 1988. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus. J. Antimicrob. Chemother. 21:461-469.
11. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
12. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
13. Chuard, C., J. C. Lucet, P. Rohner, M. Herrmann, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1991. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J. Infect. Dis. 163:1369-1373.
14. Deshpande, L., P. R. Rhomberg, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75.
15. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
16. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, and the SENTRY Participants Group. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada. Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:S114-S132.
17. Eliopoulos, G. M. 2004. Current and new antimicrobial agents. Am. Heart J. 147:587-592.
18. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
19. Geisel, R., F. J. Schmitz, A. C. Fluit, and H. Labischinski. 2001. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 20:685-697.
20. Gemmell, C. G. 2004. Glycopeptide resistance in Staphylococcus aureus: is it a real threat? J. Infect. Chemother. 10:69-75.
21. Goldstein, F. W., and M. D. Kitzis. 2003. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin. Microbiol. Infect. 9:761-765.
22. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
23. Heller, S., E. Marrer, M. G. Page, S. Shapiro, and L. Thenoz. 2005. Development of endogenous resistance by staphylococci to BAL9141 and comparators. Clin. Microbiol. Infect. 10(Suppl. 3):163.
24. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
25. Issa, N. C., M. S. Rouse, K. E. Piper, W. R. Wilson, J. M. Steckelberg, and R. Patel. 2004. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48:73-75.
26. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenhach. 2002. In vitro evaluation of BAL9141, a novel parenteral ccphalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
27. Kosowska, K., D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942.
28. Linares, J. 2001. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7(Suppl. 4):8-15.
29. Liu, C., and H. F. Chambers. 2003. Staphylococcuns aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
30. Long, T. E. 2003. Recent progress toward the clinical development of new anti-MRSA antibiotics. Investig. Drugs 6:351-359.
31. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Investig. 111:1265-1273.
32. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
33. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
34. Rosner, B. 1990. Fundamentals of biostatistics. Duxbury Press, Belmont, CA.
35. Schaad, H. J., C. Chuard, P. Vaudaux, P. Rohner, F. A. Waldvogel, and D. P. Lew. 1994. Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus. J. Antimicrob. Chcmother. 33:1191-1200.
36. Schaad, H. J., C. Chuard, P. Vaudaux, F. A. Waldvogel, and U. P. Lew. 1994. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chcmother. 38:1703-1710.
37. Schmitt-Hoffmann, A., L. Nyman, B. Roos, M. Schleimer, J. Sauer, N. Nashed, T. Brown, A. Man, and E. Weidekamm. 2004. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2576-2580.
38. Schmitt-Hoffmann, A., B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovacs. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575.
39. Tabaqchali, S. 1997. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 350:1644-1645.
40. Tenover, F. C., J. W. Biddle, and M. V. Lancaster. 2001. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7:327-332.
41. Vaudaux, P. 1998. Phenotypic antibiotic tolerance of Staphylococcus aureus in implant-related infections: relationship with in vitro colonization of artificial surfaces. Drug Resist. Updates 1:352-357.
42. Vaudaux, P., P. Francois, B. Berger-Bächi, and D. Lew. 2001. In vivo emergence of subpopulations expressing teicoplanin or vancomycin-resistant phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother. 47:163-170.
43. Vaudaux, P., P. Francois, C. Bisognano, D. Li, D. P. Lew, and J. Schrenzel. 2003. Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign-body infection due to Staphylococcus aureus. J. Antimicrob. Chemother. 52:89-95.
44. Vaudaux, P., P. Francois, C. Bisognano, J. Schrenzel, and D. P. Lew. 2002. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental forcign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:1503-1509.
45. Waldvogel, F. A., and A. L. Bisno. 2000. Infections associated with indwelling medical devices. American Society for Microbiology, Washington, D.C.
46. Walsh, T. R., and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675.
47. Whitener, C. J., S. Y. Park, F. A. Browne, L. J. Parent, K. Julian, B. Bozdogan, P. C. Appelbaum, J. Chaitram, L. M. Weigel, J. Jernigan, L. K. McDougal, F. C. Tenover, and S. K. Fridkin. 2004. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38:1049-1055.
48. Ziglam, H., and D. Nathwani. 2003. New therapeutic agents for resistant Gram-positive infections. Expert Rev. Anti. Infect. Ther. 1:655-665.
49. Zimmerli, W., F. A. Waldvogel, P. Vaudaux, and U. E. Nydegger. 1982. Pathogenesis of foreign-body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497.